Biological therapy with monoclonal antibodies: a novel treatment approach to autoimmune disease
Most autoimmune diseases (ADs) are still associated with high morbidity and mortality despite the use of a wide range of drugs that can delay their progression, control their symptoms, but never bring about a complete cure. This failure has aroused interest in new forms of monoclonal antibody-based...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental medicine 2005-12, Vol.5 (4), p.141-160 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 160 |
|---|---|
| container_issue | 4 |
| container_start_page | 141 |
| container_title | Clinical and experimental medicine |
| container_volume | 5 |
| creator | Prete, M Perosa, F Favoino, E Dammacco, F |
| description | Most autoimmune diseases (ADs) are still associated with high morbidity and mortality despite the use of a wide range of drugs that can delay their progression, control their symptoms, but never bring about a complete cure. This failure has aroused interest in new forms of monoclonal antibody-based experimental immunotherapy (IT), aiming at targeting cellular antigens or cytokines involved in the pathogenesis of ADs. The first part of this review offers a general overview of the molecular mechanisms that mediate the immune response and the molecule regarded as potential IT targets. A critical evaluation will then be made of some forms of IT, with particular emphasis on TNF-alpha and CD20-blocking reagents. Lastly an account will be given of active IT whereby an endogenous response against antigens regarded as the target of passive IT can be induced by anti-idiotype or peptides. |
| doi_str_mv | 10.1007/s10238-005-0080-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68902788</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>944156021</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-438d63da4b4736c694364fa1b188ec28022e5825d7e5fabb2208a561e0f843b73</originalsourceid><addsrcrecordid>eNpdkEtLxDAQgIMo7rr6A7xI8OCtmkfzqDddfMGCFz2HtJ26WdqmNqmy_97ILggehhmGb4aZD6FzSq4pIeomUMK4zggRKTTJxAGaU1HQrBBMH-5rrQsyQychbAihQnNyjGZUcslUkc-RuXe-9R-usi2OaxjtsMXfLq5x53tftb5PfdtHV_raQbjFFvf-CxI7go0d9BHbYRi9rdY4emyn6F3XTT3g2gWwAU7RUWPbAGf7vEDvjw9vy-ds9fr0srxbZRVnMmY517Xktc3LXHFZySLnMm8sLanWUDFNGAOhmagViMaWJWNEWyEpkEbnvFR8ga52e9MxnxOEaDoXKmhb24OfgpHJAlNaJ_DyH7jx05jeDIZxIpXSiiWI7qBq9CGM0JhhdJ0dt4YS86ve7NSbpN78qjcizVzsF09lB_XfxN41_wFu-n8h</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>230677872</pqid></control><display><type>article</type><title>Biological therapy with monoclonal antibodies: a novel treatment approach to autoimmune disease</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Prete, M ; Perosa, F ; Favoino, E ; Dammacco, F</creator><creatorcontrib>Prete, M ; Perosa, F ; Favoino, E ; Dammacco, F</creatorcontrib><description>Most autoimmune diseases (ADs) are still associated with high morbidity and mortality despite the use of a wide range of drugs that can delay their progression, control their symptoms, but never bring about a complete cure. This failure has aroused interest in new forms of monoclonal antibody-based experimental immunotherapy (IT), aiming at targeting cellular antigens or cytokines involved in the pathogenesis of ADs. The first part of this review offers a general overview of the molecular mechanisms that mediate the immune response and the molecule regarded as potential IT targets. A critical evaluation will then be made of some forms of IT, with particular emphasis on TNF-alpha and CD20-blocking reagents. Lastly an account will be given of active IT whereby an endogenous response against antigens regarded as the target of passive IT can be induced by anti-idiotype or peptides.</description><identifier>ISSN: 1591-8890</identifier><identifier>EISSN: 1591-9528</identifier><identifier>DOI: 10.1007/s10238-005-0080-5</identifier><identifier>PMID: 16362794</identifier><identifier>CODEN: CEMLBA</identifier><language>eng</language><publisher>Italy: Springer Nature B.V</publisher><subject>Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - therapeutic use ; Antigens ; Autoimmune diseases ; Autoimmune Diseases - drug therapy ; Drug therapy ; Humans ; Immune system ; Immunoglobulins ; Medical treatment ; Peptides</subject><ispartof>Clinical and experimental medicine, 2005-12, Vol.5 (4), p.141-160</ispartof><rights>Springer-Verlag Italia 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c326t-438d63da4b4736c694364fa1b188ec28022e5825d7e5fabb2208a561e0f843b73</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16362794$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Prete, M</creatorcontrib><creatorcontrib>Perosa, F</creatorcontrib><creatorcontrib>Favoino, E</creatorcontrib><creatorcontrib>Dammacco, F</creatorcontrib><title>Biological therapy with monoclonal antibodies: a novel treatment approach to autoimmune disease</title><title>Clinical and experimental medicine</title><addtitle>Clin Exp Med</addtitle><description>Most autoimmune diseases (ADs) are still associated with high morbidity and mortality despite the use of a wide range of drugs that can delay their progression, control their symptoms, but never bring about a complete cure. This failure has aroused interest in new forms of monoclonal antibody-based experimental immunotherapy (IT), aiming at targeting cellular antigens or cytokines involved in the pathogenesis of ADs. The first part of this review offers a general overview of the molecular mechanisms that mediate the immune response and the molecule regarded as potential IT targets. A critical evaluation will then be made of some forms of IT, with particular emphasis on TNF-alpha and CD20-blocking reagents. Lastly an account will be given of active IT whereby an endogenous response against antigens regarded as the target of passive IT can be induced by anti-idiotype or peptides.</description><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antigens</subject><subject>Autoimmune diseases</subject><subject>Autoimmune Diseases - drug therapy</subject><subject>Drug therapy</subject><subject>Humans</subject><subject>Immune system</subject><subject>Immunoglobulins</subject><subject>Medical treatment</subject><subject>Peptides</subject><issn>1591-8890</issn><issn>1591-9528</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkEtLxDAQgIMo7rr6A7xI8OCtmkfzqDddfMGCFz2HtJ26WdqmNqmy_97ILggehhmGb4aZD6FzSq4pIeomUMK4zggRKTTJxAGaU1HQrBBMH-5rrQsyQychbAihQnNyjGZUcslUkc-RuXe-9R-usi2OaxjtsMXfLq5x53tftb5PfdtHV_raQbjFFvf-CxI7go0d9BHbYRi9rdY4emyn6F3XTT3g2gWwAU7RUWPbAGf7vEDvjw9vy-ds9fr0srxbZRVnMmY517Xktc3LXHFZySLnMm8sLanWUDFNGAOhmagViMaWJWNEWyEpkEbnvFR8ga52e9MxnxOEaDoXKmhb24OfgpHJAlNaJ_DyH7jx05jeDIZxIpXSiiWI7qBq9CGM0JhhdJ0dt4YS86ve7NSbpN78qjcizVzsF09lB_XfxN41_wFu-n8h</recordid><startdate>200512</startdate><enddate>200512</enddate><creator>Prete, M</creator><creator>Perosa, F</creator><creator>Favoino, E</creator><creator>Dammacco, F</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>200512</creationdate><title>Biological therapy with monoclonal antibodies: a novel treatment approach to autoimmune disease</title><author>Prete, M ; Perosa, F ; Favoino, E ; Dammacco, F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-438d63da4b4736c694364fa1b188ec28022e5825d7e5fabb2208a561e0f843b73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antigens</topic><topic>Autoimmune diseases</topic><topic>Autoimmune Diseases - drug therapy</topic><topic>Drug therapy</topic><topic>Humans</topic><topic>Immune system</topic><topic>Immunoglobulins</topic><topic>Medical treatment</topic><topic>Peptides</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Prete, M</creatorcontrib><creatorcontrib>Perosa, F</creatorcontrib><creatorcontrib>Favoino, E</creatorcontrib><creatorcontrib>Dammacco, F</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Prete, M</au><au>Perosa, F</au><au>Favoino, E</au><au>Dammacco, F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biological therapy with monoclonal antibodies: a novel treatment approach to autoimmune disease</atitle><jtitle>Clinical and experimental medicine</jtitle><addtitle>Clin Exp Med</addtitle><date>2005-12</date><risdate>2005</risdate><volume>5</volume><issue>4</issue><spage>141</spage><epage>160</epage><pages>141-160</pages><issn>1591-8890</issn><eissn>1591-9528</eissn><coden>CEMLBA</coden><abstract>Most autoimmune diseases (ADs) are still associated with high morbidity and mortality despite the use of a wide range of drugs that can delay their progression, control their symptoms, but never bring about a complete cure. This failure has aroused interest in new forms of monoclonal antibody-based experimental immunotherapy (IT), aiming at targeting cellular antigens or cytokines involved in the pathogenesis of ADs. The first part of this review offers a general overview of the molecular mechanisms that mediate the immune response and the molecule regarded as potential IT targets. A critical evaluation will then be made of some forms of IT, with particular emphasis on TNF-alpha and CD20-blocking reagents. Lastly an account will be given of active IT whereby an endogenous response against antigens regarded as the target of passive IT can be induced by anti-idiotype or peptides.</abstract><cop>Italy</cop><pub>Springer Nature B.V</pub><pmid>16362794</pmid><doi>10.1007/s10238-005-0080-5</doi><tpages>20</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1591-8890 |
| ispartof | Clinical and experimental medicine, 2005-12, Vol.5 (4), p.141-160 |
| issn | 1591-8890 1591-9528 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68902788 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antigens Autoimmune diseases Autoimmune Diseases - drug therapy Drug therapy Humans Immune system Immunoglobulins Medical treatment Peptides |
| title | Biological therapy with monoclonal antibodies: a novel treatment approach to autoimmune disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T01%3A49%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biological%20therapy%20with%20monoclonal%20antibodies:%20a%20novel%20treatment%20approach%20to%20autoimmune%20disease&rft.jtitle=Clinical%20and%20experimental%20medicine&rft.au=Prete,%20M&rft.date=2005-12&rft.volume=5&rft.issue=4&rft.spage=141&rft.epage=160&rft.pages=141-160&rft.issn=1591-8890&rft.eissn=1591-9528&rft.coden=CEMLBA&rft_id=info:doi/10.1007/s10238-005-0080-5&rft_dat=%3Cproquest_cross%3E944156021%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=230677872&rft_id=info:pmid/16362794&rfr_iscdi=true |